WSJ: FDA to reverse rejection of Regenxbio rare-disease drug

• Regenxbio will refile its application for Navsunli in Q3 after a formal FDA meeting expected in July
• The FDA originally rejected the rare-disease gene therapy in February due to concerns about trial design uncertainty
• The reversal allows Regenxbio another opportunity to gain approval for treating Hunter syndrome, a rare genetic disorder

Summary: FDA to Reverse Rejection of Regenxbio's Rare Disease Gene Therapy

The U.S. Food and Drug Administration (FDA) will reverse its previous rejection of Regenxbio's gene therapy Navsunli, designed to treat Hunter syndrome, according to a Wall Street Journal report published June 22.

Key Developments

Regenxbio plans to refile its application in the third quarter, following a formal meeting with the FDA expected in July. CEO Curran Simpson confirmed the company's intention to resubmit the application for the rare-disease treatment.

Background

In February, the FDA rejected Navsunli, citing uncertainty over trial design. Hunter syndrome is a rare genetic disorder, making this gene therapy a potentially significant treatment option for a limited patient population.

Market Implications

This reversal represents a positive development for Regenxbio, offering the company a second opportunity to gain FDA approval for its gene therapy. The decision suggests the FDA may be open to addressing previous concerns through revised application materials and discussions.

The gene therapy sector continues to face regulatory scrutiny, particularly around trial design and efficacy data. However, the FDA's willingness to reconsider its position indicates potential flexibility in evaluating treatments for rare diseases where patient populations are small and traditional trial designs may be challenging.

For investors, this news could signal renewed optimism for Regenxbio's pipeline and revenue potential, though approval remains contingent on addressing the FDA's previous concerns about trial methodology. The third-quarter timeline provides a specific window for market participants to monitor.